EQS-News: Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

EQS

Im Artikel erwähnte Wertpapiere: Context Therap Rg

EQS-News: Context Therapeutics
Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

06.12.2022 / 12:40 CET/CEST
The issuer is solely responsible for the content of this announcement.


0.jpgContact Details

Proactive Investors USA

Proactive Investors USA

+1 347-449-0879

na-editorial@proactiveinvestors.com


News Source: News Direct


06.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Context Therapeutics
United States
ISIN: US21077P1084
EQS News ID: 1506291

 
End of News EQS News Service

1506291  06.12.2022 CET/CEST

Im Artikel erwähnte Wertpapiere

Context Therap Rg 1,38 0,00%
close

Populäre Aktien